Evidence map›Paper›PMID 39965925›Full record

ArticleJournal of proteome research2025

Epitope and Paratope Mapping of a SUMO-Remnant Antibody Using Cross-Linking Mass Spectrometry and Molecular Docking.

Simon Comtois-Marotte, Éric Bonneil, Chongyang Li, Matthew J Smith, Pierre Thibault

Abstract read
In one paragraph

Article in Journal of proteome research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Simon Comtois-MarotteInstitute for Research in Immunology and Cancer (IRIC) Université de Montréal, Montreal, Quebec H3T 1J4, Canada.
Éric BonneilInstitute for Research in Immunology and Cancer (IRIC) Université de Montréal, Montreal, Quebec H3T 1J4, Canada.ORCID 0000-0002-4039-3131
Chongyang LiInstitute for Research in Immunology and Cancer (IRIC) Université de Montréal, Montreal, Quebec H3T 1J4, Canada.ORCID 0000-0001-6842-4406
Matthew J SmithInstitute for Research in Immunology and Cancer (IRIC) Université de Montréal, Montreal, Quebec H3T 1J4, Canada.
Pierre ThibaultInstitute for Research in Immunology and Cancer (IRIC) Université de Montréal, Montreal, Quebec H3T 1J4, Canada.ORCID 0000-0001-5993-0331

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The small ubiquitin-like modifier (SUMO) is an important post-translational modification that regulates the function of various proteins essential for DNA damage repair, genome integrity, and cell homeostasis. To identify protein SUMOylation effectively, an enrichment step is necessary, often requiring exogenous gene expression in cells and immunoaffinity purification of SUMO-remnant peptides following tryptic digestion. Previously, an antibody was developed to enrich tryptic peptides containing the remnant NQTGG on the receptor lysine, although the specifics of the structural interaction motif remained unclear. This study integrates

Indexed as

AntibodiesEpitope MappingEpitopesMolecular Docking SimulationSmall Ubiquitin-Related Modifier ProteinsSUMO-1 ProteinAmino Acid SequenceCross-Linking ReagentsHumansMass SpectrometryPeptidesProtein Processing, Post-TranslationalSumoylationAntibodiesCross-Linking ReagentsEpitopesPeptidesSmall Ubiquitin-Related Modifier ProteinsSUMO-1 Proteinantibodycross-linkingmass spectrometrymolecular dockingparatope mappingSUMO

Identifiers

PMID39965925
PMCPMC11895775

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.